Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | INMT | O95050 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL252362 | 0.79 | POLB (0.39) | USP2INMTPOLB | |
| SCHEMBL23571886 | 0.79 | INMT (0.38) | USP2INMTPOLB | |
| SCHEMBL16234596 | 0.77 | CYP1A2 (0.31) | — | |
| SCHEMBL251940 | 0.76 | CYP2D6 (0.42) | USP2INMTPOLB | |
| SCHEMBL252252 | 0.76 | CYP2D6 (0.35) | — | |
| SCHEMBL23075885 | 0.76 | USP2 (0.35) | USP2INMT | |
| SCHEMBL22106057 | 0.76 | USP2 (0.35) | USP2INMT | |
| SCHEMBL23075888 | 0.76 | USP2 (0.35) | USP2INMT | |
| SCHEMBL9818798 | 0.76 | PIK3CD (0.46) | PIK3CD | |
| SCHEMBL14572911 | 0.76 | USP2 (0.35) | USP2INMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640641-B2 | Curable coating compositions of silane functional polymers | KING INDUSTRIES (US) | 2020-05-05 | — | — | US | claimed |
| US-20200062953-A1 | CURABLE COATING COMPOSITIONS OF SILANE FUNCTIONAL POLYMERS | KING INDUSTRIES | 2020-02-27 | — | — | US | claimed |
| US-20190248721-A1 | PROCESSES FOR PREPARING CALIXARENES | SI GROUP, INC. | 2019-08-15 | — | — | US | claimed |
| WO-2019157357-A1 | PROCESSES FOR PREPARING CALIXARENES | SI GROUP, INC. (US) | 2019-08-15 | — | — | WO | claimed |
| US-10336863-B2 | Curable composition having a special catalyst/softner system | HENKEL AG & CO. KGAA (DE) | 2019-07-02 | — | — | US | claimed |
| US-20180237635-A1 | CURABLE COATING COMPOSITIONS OF SILANE FUNCTIONAL POLYMERS | KING INDUSTRIES | 2018-08-23 | — | — | US | claimed |
| US-9976028-B2 | Curable coating compositions of silane functional polymers | KING INDUSTRIES (US) | 2018-05-22 | — | — | US | claimed |
| EP-1930376-B2 | CURABLE COMPOSITION | KANEKA CORP (JP) | 2016-09-07 | — | — | EP | claimed |
| WO-2016137881-A1 | CURABLE COATING COMPOSITIONS OF SILANE FUNCTIONAL POLYMERS | KING INDUSTRIES (US) | 2016-09-01 | — | — | WO | claimed |
| US-20160244606-A1 | CURABLE COATING COMPOSITIONS OF SILANE FUNCTIONAL POLYMERS | KING INDUSTRIES | 2016-08-25 | — | — | US | claimed |
| WO-2012036392-A3 | HUMAN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR FAB ANTIBODY AND A PHARMACEUTICAL COMPOSITION FOR TREATING TUMOURS COMPRISING THE SAME | 주식회사 아이지세라피 (KR) | 2012-05-10 | — | — | WO | claimed |
| EP-1930376-B1 | CURABLE COMPOSITION | KANEKA CORP (JP) | 2011-12-07 | — | — | EP | claimed |
| US-8013080-B2 | Curable composition | KANEKA CORPORATION (JP) | 2011-09-06 | — | — | US | claimed |
| US-12049440-B2 | Processes for preparing calixarenes | SI GROUP, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20220177397-A1 | PROCESSES FOR PREPARING CALIXARENES | SI GROUP, INC. | 2022-06-09 | — | — | US | disclosed |
| US-11225450-B2 | Processes for preparing calixarenes | SI GROUP, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| EP-1930376-B1 | CURABLE COMPOSITION | KANEKA CORP (JP) | 2011-12-07 | — | — | EP | disclosed |
| US-8013080-B2 | Curable composition | KANEKA CORPORATION (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20090171025-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-1930376-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248721-A1 | PROCESSES FOR PREPARING CALIXARENES | CALU, CALD1, CALR | PIK3CD 4096/4885USP2 3712/4885INMT 3966/4885 |
| US-11225450-B2 | Processes for preparing calixarenes | CALU, CALD1, CALR | PIK3CD 4096/4885USP2 3712/4885INMT 3966/4885 |
| US-20220177397-A1 | PROCESSES FOR PREPARING CALIXARENES | CALU, CALD1, CALR | PIK3CD 4096/4885USP2 3712/4885INMT 3966/4885 |
| US-12049440-B2 | Processes for preparing calixarenes | CALU, CALD1, CALR | PIK3CD 4096/4885USP2 3712/4885INMT 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.